CDK1 and CCNB1 have been reported to promote the development of glioblastoma malignancies [9] and are considered potential prognostic biomarkers or therapeutic targets for patients with hepatocellular carcinoma [10, 11]. This evidence concerns the gene CCNB1 and hepatocellular carcinoma.